GDRXGoodRx Holdings, Inc.
Price
-22%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: growth
Quality strong, nothing alarming, undemanding price, growth fading, the market undecided.
Charts
As reported to the SEC, without any scoring.
GoodRx Holdings, Inc. (GDRX) reported revenue of $200M in Q2 2026 (quarter ended Jun 30, 2026), down 1.3% from the same quarter a year earlier. That came with a gross margin of 90% and net income of $8.5M (4.3% of revenue). For the full year FY2025, revenue was $797M (+0.6% year on year) and net income $30M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-Over-Year.Earnings release · press release
- May 6, 2026Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter.Earnings release · press release
- Apr 24, 2026Chief Accounting Officer Appointment On April 23, 2026, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Thomas Chan, Vice President, Corporate Controller of the Company as the Company’s Chief Accounting Officer and designated Mr. Chan as the principal accounting officer of the …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Health Information Services
Ranks #5 of 20 by RyuScore